Stock SMMT SUMMIT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
4.65 USD -2.72% Intraday chart for Summit Therapeutics Inc. +5.92% +78.16%
May. 07 Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target MT
May. 01 Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024

Valuation

Fiscal Period: December 2019 2020 2023 2024 2025 2026
Capitalization 1 70.45 282.7 1,437 2,608 - -
Enterprise Value (EV) 1 70.45 282.7 1,437 2,608 2,608 2,608
P/E ratio -9.28 x - -2.62 x - - -
Yield - - - - - -
Capitalization / Revenue 4.47 x 19.4 x - - - 263 x
EV / Revenue 4.47 x 19.4 x - - - 263 x
EV / EBITDA - - - -18.7 x -16.4 x -15 x
EV / FCF - - - -21.2 x -15.3 x -10.7 x
FCF Yield - - - -4.72% -6.55% -9.36%
Price to Book - - - - - -
Nbr of stocks (in thousands) 335,890 82,260 700,843 701,980 - -
Reference price 2 1.207 3.437 2.050 3.716 3.716 3.716
Announcement Date 4/30/20 3/17/21 2/20/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2023 2024 2025 2026
Net sales 1 15.75 14.54 - - - 9.927
EBITDA 1 - - - -139.5 -158.8 -174.1
EBIT 1 -25.33 -38.35 - -144.9 -175.4 -218.3
Operating Margin -160.88% -263.7% - - - -2,199.41%
Earnings before Tax (EBT) -25.56 - - - - -
Net income -22.03 - -486.2 - - -
Net margin -139.92% - - - - -
EPS -0.1300 - -0.7828 - - -
Free Cash Flow 1 - - - -123.2 -170.9 -244
FCF margin - - - - - -2,458.14%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/30/20 3/17/21 2/20/24 - - -
1GBP in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - -
EBITDA 1 - -35.59 -35.16 -34.82 - -
EBIT 1 -33.85 -36.24 -37.21 -37.43 -41.62 -44.02
Operating Margin - - - - - -
Earnings before Tax (EBT) - - - - - -
Net income - - - - - -
Net margin - - - - - -
EPS - - - - - -
Dividend per Share - - - - - -
Announcement Date 5/1/24 - - - - -
1GBP in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - - - -123 -171 -244
ROE (net income / shareholders' equity) - - - -155% -100% -135%
ROA (Net income/ Total Assets) - - - - - -
Assets - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 1 - - - - - 0.08
Capex / Sales - - - - - 0.8%
Announcement Date 4/30/20 3/17/21 2/20/24 - - -
1GBP in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.716 GBP
Average target price
5.994 GBP
Spread / Average Target
+61.30%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SUMMIT THERAPEUTICS INC. Stock Summit Therapeutics Inc.
+78.16% 3.26B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
ARGENX SE Stock argenx SE
+1.28% 22.25B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
GENMAB A/S Stock Genmab A/S
-7.05% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SMMT Stock
  4. Financials Summit Therapeutics Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW